Morepen Laboratories share news and announcements
NSE: MOREPENLABBSE: 500288Pharmaceuticals & BiotechnologySmall Cap
Last close ₹123.54up ₹5.87 (4.99%)BSE ₹123.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹117.67.
52-week range of traded prices to 23 Oct 2026
₹33.05Low, 30 Mar 2026₹150.70High, 7 Oct 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹6,769 Cr1,108th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 4 Aug 2026
- 48.2
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹26 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 59.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 5.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.16%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 4 Aug 2026
- 11.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹26 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 9.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 4 Aug 2026
- 10.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.16
- Volume, NSEVolume. Shares traded on the last trading day.
- 50,63,581
Morepen Laboratories board meetings
128 filed, newest first. Page 2 of 3.
Nov 2019
Sep 2019
26 Sep · Board meeting
19 Sep · Board meeting
16 Sep · Board meeting
Aug 2019
13 Aug · Board meeting
May 2019
4 May · Board meeting
Apr 2019
Mar 2019
30 Mar · Board meeting
Feb 2019
4 Feb · Board meeting
Jan 2019
Nov 2018
1 Nov · Board meeting
Oct 2018
Aug 2018
13 Aug · Board meeting
Jul 2018
May 2018
16 May · Board meeting
Jan 2018
Nov 2017
10 Nov · Board meeting
Sep 2017
Apr 2017
Jan 2017
Nov 2016
Oct 2016
Sep 2016
Jul 2016
29 Jul · Board meeting
Inter-alia, to consider, approve and take on record the Un-Audited Financial Results of the Company for the Quarter ended June 30, 2016.
May 2016
Jan 2016
Nov 2015
Oct 2015
Jul 2015
May 2015
4 May · Board meeting
Inter-alia, to consider, approve and take on record the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2015.
Jan 2015
30 Jan · Board meeting
Inter-alia, to consider, approve and take on record the Un-audited Financial Results of the Company for the Quarter and Nine months ended 31st December, 2014.
Nov 2014
Jul 2014
May 2014
Feb 2014
Nov 2013
Jul 2013
26 Jul · Board meeting
To consider and take on record inter alia the Un-audited Financial Results of the Company for the quarter ended on June 30, 2013.
May 2013
3 May · Board meeting
To consider and take on record inter alia the audited Financial Results of the Company for the year ended on March 31, 2013.
Jan 2013
29 Jan · Board meeting
To consider and take on record inter alia the un-audited Financial Results of the Company for the quarter ended on December 31, 2012.
Oct 2012
23 Oct · Board meeting
To consider and take on record interalia the Un-audited Financial Results of the Company for the Quarter ended on September 30, 2012.
Jul 2012
31 Jul · Board meeting
To consider and take on record inter alia the Un-audited Financial Results of the Company for the quarter ended on June 30, 2012.
May 2012
4 May · Board meeting
To consider and take on record inter alia the audited Financial Results of the Company for the year ended on March 31, 2012.
Feb 2012
1 Feb · Board meeting
To consider and take on record inter alia the un-audited Financial Results of the Company for the quarter ended on December 31, 2011.